WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries
Share this article Share this article STOCKHOLM and HANGZHOU, China, Dec. 30, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti ® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti ® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is grante...
Source: prnewswire.com
